The GH/IGF-1 Axis: How Growth Hormone Peptides Work

Growth hormone (GH) secretion is controlled by a tightly regulated feedback loop involving the hypothalamus, anterior pituitary gland, and peripheral tissues.

The key players: - GHRH (Growth Hormone-Releasing Hormone): Produced in the hypothalamus, stimulates pituitary somatotroph cells to synthesise and release GH - Somatostatin (GHIH): Also hypothalamic, acts as the brake — it inhibits GH release from the pituitary - Ghrelin/GHS receptor: Stomach-derived ghrelin acts on pituitary GHS receptors to amplify GH release independently of GHRH

The pulsatile pattern: GH is not released continuously. It follows a pulsatile pattern with the largest pulses occurring during deep sleep (stages 3–4). This pulsatility is critical — continuous GH exposure actually downregulates receptor sensitivity.

Negative feedback: - GH stimulates IGF-1 production in the liver - Rising IGF-1 feeds back to the hypothalamus and pituitary, suppressing further GH release - GH itself also provides short-loop negative feedback

Understanding this axis is essential for appreciating how different peptides stimulate GH through distinct mechanisms.

GHRH analogue peptides mimic the body's natural GHRH, binding to the same GHRH receptor on pituitary somatotroph cells.

Sermorelin The first 29 amino acids of the 44-amino-acid GHRH molecule, retaining full biological activity: - Binds the GHRH receptor on the pituitary - Stimulates GH synthesis and pulsatile release - Short half-life (~10–20 minutes) limits sustained effect - FDA-approved historically for GH deficiency diagnosis

CJC-1295 (with DAC) A modified GHRH analogue with a Drug Affinity Complex: - The DAC modification binds to albumin, extending half-life to ~6–8 days - Produces sustained GH elevation rather than sharp pulses - This extended profile is debated — some researchers argue the loss of pulsatility may be suboptimal

CJC-1295 (without DAC / Mod GRF 1-29) The same core peptide without the albumin-binding modification: - Half-life of ~30 minutes - Produces more physiological GH pulses - Often combined with ghrelin mimetics for synergistic effect

Tesamorelin A GHRH analogue approved for HIV-associated lipodystrophy: - The only GH secretagogue peptide with current FDA approval for a specific indication - Reduces visceral adipose tissue whilst maintaining GH pulsatility

Ghrelin mimetics (growth hormone secretagogues) work through a different receptor — the GHS-R1a (ghrelin receptor) — providing a complementary mechanism to GHRH analogues.

Ipamorelin Considered the most selective ghrelin mimetic: - Stimulates GH release without significantly affecting cortisol, prolactin, or ACTH - This selectivity distinguishes it from older GHRPs - Produces robust GH pulses when combined with a GHRH analogue

GHRP-6 and GHRP-2 Earlier ghrelin mimetics with broader hormonal effects: - Stimulate GH release effectively but also increase cortisol and prolactin - GHRP-6 strongly stimulates appetite through ghrelin receptor activation - GHRP-2 is somewhat more selective than GHRP-6 but less so than ipamorelin

MK-677 (Ibutamoren) A non-peptide, orally active ghrelin mimetic: - Technically not a peptide — it is a small molecule that activates the ghrelin receptor - Oral bioavailability makes it uniquely convenient - Produces sustained GH and IGF-1 elevation over 24 hours - Notable side effects include increased appetite and potential insulin resistance with long-term use

Synergy: Combining a GHRH analogue with a ghrelin mimetic amplifies GH release beyond what either achieves alone, as they activate two independent pathways simultaneously.

From around age 30, GH secretion declines by approximately 14% per decade — a phenomenon termed "somatopause."

What changes with age: - Reduced amplitude of GH pulses (the peaks get smaller) - Decreased frequency of GH pulses - Lower baseline IGF-1 levels - Reduced hypothalamic GHRH output - Increased somatostatin tone (the brake is applied more strongly)

Clinical consequences of low GH/IGF-1: - Decreased lean body mass and increased visceral adiposity - Reduced bone mineral density - Impaired exercise capacity and recovery - Changes in body composition, skin thickness, and sleep quality

The debate: Whether somatopause represents a treatable "deficiency" or a normal adaptive process remains contentious: - Some endocrinologists argue that low GH in ageing is protective (reducing cancer risk) - Others view it as a contributor to age-related decline that warrants intervention - The mainstream medical position is that GH therapy is only indicated for diagnosed GH deficiency, not normal ageing

GH secretagogue peptides have generated interest precisely because they work through the body's natural axis rather than replacing GH directly, theoretically maintaining feedback regulation.

Many of growth hormone's effects are not direct — they are mediated through insulin-like growth factor 1 (IGF-1), produced primarily in the liver.

GH vs IGF-1 effects: - Direct GH effects: Lipolysis (fat breakdown), insulin antagonism, fluid retention - IGF-1-mediated effects: Muscle protein synthesis, bone growth, cellular proliferation - Overlapping effects: Both contribute to connective tissue repair and recovery

IGF-1 biology: - Circulates bound to IGF-binding proteins (IGFBPs), primarily IGFBP-3 - Free IGF-1 is the biologically active fraction - IGF-1 has a much longer half-life than GH (~15–20 hours vs 20 minutes) - This is why IGF-1 blood levels are used clinically to assess GH status

Clinical monitoring: When using GH secretagogue peptides, serum IGF-1 is the primary biomarker: - Baseline IGF-1 before starting any peptide protocol - Follow-up IGF-1 at 4–6 weeks to assess response - Target range: age-appropriate upper-normal (not supraphysiological) - Excessively elevated IGF-1 may increase risks including theoretical cancer concerns

*This article is for educational purposes only. GH secretagogue peptides should only be used under medical supervision with appropriate blood work monitoring. Self-administration without medical oversight carries significant risks.*